Liang Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Liang Liang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Bo-Lin Zhu
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publication- Daihong Liu
School of Medicine, Nankai University, Tianjin, China
1 shared publication - Daobin Zhou
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication Di Chen
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publicationFei Zhao
Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, (Beijing Hospital)
1 shared publication- Guo-Rui Ruan
Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People’s Hospital, Peking University, Beijing 100044, China
1 shared publication
Latest Publications
- Open Access
- 31 August 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2551822
Risk factors of linezolid-associated hyponatremia from a retrospective case–control study: decreased serum albumin as a selective predictor in elder patients
The incidence of linezolid-associated hyponatremia is approximately 20% in real-world studies. However, there are limited case reports and rare research on linezolid-induced hyponatremia. This study aims to identify risk factors associated with linezolid-induced hyponatremia, particularly in older patients. This retrospective study was conducted from January 2018 to December 2023. Patients aged over 18 years who received linezolid for at least three days at Beijing Hospital were included. Statistical analyses were performed using SPSS Statistics version 19. 68 patients were identified in the hyponatremia group, with 68 matched individuals by sex and age in the control group. Binary logistic regression analysis revealed that a history of cardiovascular disease, estimated glomerular filtration rate, and the duration of linezolid therapy were risk factors for hyponatremia. Subgroup analysis in patients age ≥ 65 identified the duration of therapy, a history of cardiovascular disease, a history of endocrine diseases, and serum albumin (ALB) decreased during linezolid therapy as key indicators of hyponatremia. A decrease in ALB during linezolid therapy is a more selective predictor of hyponatremia than baseline ALB. Linezolid-induced hyponatremia is associated with adverse outcomes, highlighting the importance of monitoring serum sodium and ALB in patients receiving this therapy.
- 31 August 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2551822
Open AccessRisk factors of linezolid-associated hyponatremia from a retrospective case–control study: decreased serum albumin as a selective predictor in elder patients
The incidence of linezolid-associated hyponatremia is approximately 20% in real-world studies. However, there are limited case reports and rare research on linezolid-induced hyponatremia. This study aims to identify risk factors associated with linezolid-induced hyponatremia, particularly in older patients. This retrospective study was conducted from January 2018 to December 2023. Patients aged over 18 years who received linezolid for at least three days at Beijing Hospital were included. Statistical analyses were performed using SPSS Statistics version 19. 68 patients were identified in the hyponatremia group, with 68 matched individuals by sex and age in the control group. Binary logistic regression analysis revealed that a history of cardiovascular disease, estimated glomerular filtration rate, and the duration of linezolid therapy were risk factors for hyponatremia. Subgroup analysis in patients age ≥ 65 identified the duration of therapy, a history of cardiovascular disease, a history of endocrine diseases, and serum albumin (ALB) decreased during linezolid therapy as key indicators of hyponatremia. A decrease in ALB during linezolid therapy is a more selective predictor of hyponatremia than baseline ALB. Linezolid-induced hyponatremia is associated with adverse outcomes, highlighting the importance of monitoring serum sodium and ALB in patients receiving this therapy.